Scientific Evidence Published

RNS Number : 3116R

Tristel PLC

02 November 2011

 



TRISTEL plc

("Tristel" or "the Company")

Scientific Evidence Published

Tristel plc (AIM: TSTL), the manufacturer of infection control, contamination control and hygiene consumable products, reports that in recent weeks, a publication in the Journal of Hospital Infection and two poster presentations at scientific congresses have added to the published body of evidence of the efficacy, ease of use and cost effectiveness of Tristel's disinfectant products.

In an evaluation of the sporicidal activity of different chemical disinfectants used in hospitals against Clostridium difficile, undertaken by S. Speight et al (2011) of the Health Protection Agency Microbiological Services, Porton Down, and published in the Journal of Hospital Infection, six out of seven of the most effective and fastest acting disinfectants tested were Tristel chlorine dioxide products.

Separately, the results of a urology clinical study were presented at the Congress of the Société Internationale d'Urologie (International Society of Urology)in Berlin in October 2011. A randomised single-blind comparison of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Johnson & Johnson's Cidex OPA (ortho-phthalaldehyde) for use with flexible cystoscopes was undertaken by P. Gilling et al at Tauranga Hospital, New Zealand. The study determined that both disinfectants had comparable efficacy, but Tristel Fuse was found to be by far the most cost effective and quickest to use.

Lastly, a case study authored by Jane Ashby of University College London Hospitals NHS Trust was presented to the United Kingdom Infection Prevention Society conference in October 2011. The study reports upon the adoption throughout all five hospitals in this major London trust of Tristel's surface disinfectants in replacement of the chlorine tablets previously used.

Paul Swinney, CEO of Tristel plc, commented: "These studies add to the substantial body of published evidence that proves Tristel's benefit to hospitals. The scientific data originates from both the United Kingdom and overseas and will help to expand Tristel presence as a major force in the global infection control market."

For further information:

Tristel plc		Tel: [phone]
Paul Swinney, Chief Executive Liz Dixon, Finance Director
Walbrook PR Ltd		Tel: [phone]
Fiona Henson		Mob: [phone] or [e-mail]
Paul McManus		Mob: [phone] or [e-mail]
FinnCap
Geoff  Nash / Charlotte Stranner (Corporate Finance)		Tel: [phone]
Simon Starr (Corporate Broking)

Reference:

Speight, S., Moy, A., Macken, S., Chitnis, R,, Hoffman, P.N., Davies, A., Bennett, A. and Walker, J.T., 2011. Evaluation of the sporicidal activity of different chemical disinfectants used in hospitals against Clostridium difficile. Journal of Hospital Infection, 79, pp. 18-22.

About Tristel plc

Tristel plc is an infection prevention and contamination control business headquartered in Newmarket, United Kingdom.  Its products are used to prevent hospital acquired infections, for hygiene in animal healthcare and by pharmaceutical and personal care manufacturers for contamination control.  Its leading brands are Tristel (infection prevention) and Crystel (contamination control).  The Group's products are considered to be amongst the highest performing biocides available to healthcare and industry.  Tristel's lead technology is a proprietary chlorine dioxide formulation used to disinfect instruments and surfaces and to control legionella and biofilm build up in water.

Tristel was admitted to the London Stock Exchange AIM market in June 2005.  Its stock exchange symbol is TSTL.

 

END

 

 

NRABBBRTMBJMBPB